Expanding access to clinical trial data responsibly
Tuesday, October 22, 2013 - 09:30
in Health & Medicine
A new report proposes recommendations for how to expand public access to data from clinical trials while protecting patients' privacy and weighing pharmaceutical companies' business interests. Recently, the European Medicines Agency announced it will provide public access to participant-level data submitted in applications for marketing approval in Europe, prompting questions about whether the US FDA should follow suit.